Join the Cervical Cancer group to help and get support from people like you.
Cervical Cancer News (Page 2)
Related terms: Cancer, Cervix
MS Might Raise a Person's Odds for Cancer
THURSDAY, Oct. 10, 2024b – There's a small but significant increased of certain cancers in people battling multiple sclerosis (MS), new research shows. Those malignancies include cancers of the...
One-Dose HPV Vaccination Averts Similar Number of Cancers as Two Doses
MONDAY, Oct. 7, 2024 – A one-dose human papillomavirus (HPV) vaccination program is projected to prevent a similar number of cervical cancers as a two-dose program, according to a study published...
U.S. Cancer Incidence Trends Lower Than Expected in 2021
FRIDAY, Sept. 6, 2024 – U.S. cancer incidence trends improved in 2021, but continued to be lower than expected, according to a study published online Sept. 6 in JAMA Network Open. Todd Burus, from...
U.S. Spends $43 Billion Annually on Cancer Screening
TUESDAY, Aug. 6, 2024 – Screening for cancer saves lives, but a new report shows it comes with a hefty price tag: The United States spends at least $43 billion annually on tests that check for five...
2007 to 2020 Saw Continuous Decrease in Cervical Cancer in Younger Women
MONDAY, Aug. 5, 2024 – For individuals younger than 25 years, the incidence of cervical intraepithelial neoplasia (CIN) decreased continuously from 2007 through 2020, according to a research letter...
Noninvasive Urine Test for Cervical Cancer Shows Promise
TUESDAY, July 9, 2024 – A new urine test might help doctors more easily screen for cervical cancer, researchers report. The test looks for proteins generated by a type of cancer-causing human...
Tisotumab Vedotin Efficacious for Recurrent Cervical Cancer
MONDAY, July 8, 2024 – Second- or third-line treatment with tisotumab vedotin is efficacious for patients with recurrent cervical cancer, according to a study published in the July 4 issue of the...
Survival Improves With Open Hysterectomy for Cervical Cancer
FRIDAY, June 28, 2024 – For patients with early-stage cervical cancer, disease-free and overall survival are lower for patients undergoing minimally invasive versus open radical hysterectomy,...
Past-Year Pap Testing Rates Were Lower in 2022 Than 2019
FRIDAY, June 14, 2024 – Past-year Papanicolaou testing rates were lower in 2022 than in 2019, overall, and lower rates were seen in rural versus urban women, according to a study published in online...
ASCO: HPV Vaccination Positively Affecting More Than Just Cervical Cancer Risk
THURSDAY, May 23, 2024 – Human papillomavirus (HPV) vaccination is associated with reduced odds of several types of HPV-related cancers, not just cervical cancer, according to a study presented at...
Time Between HPV Tests for Cervical Cancer Might Be Safely Extended
WEDNESDAY, May 22, 2024 – HPV testing to prevent cervical cancer might not have to happen as often as currently recommended, a new study says. Current standards require women to undergo human...
FDA Approves First Self-Test Collection Kit for HPV
WEDNESDAY, May 15, 2024 – The U.S. Food and Drug Administration has approved a kit that will allow women to collect their own vaginal sample for HPV screening, a move that could increase early...
FDA Grants Full Approval for Tivdak to Treat Recurrent or Metastatic Cervical Cancer
NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE) April 29, 2024 – Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for Keytruda in cervical cancer and...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...